Figure S1. Effect of baseline covariates on exposure parameter AUC_{ss}.

Solid black vertical line and blue square show steady state tremelimumab exposure level for a typical patient (male, with baseline values of CRP of 33 mg/L, and target lesion tumor size of 95.6 mm).

Light grey area shows 30% change from the typical patient; dark grey delineated by dotted black lines shows 20% change. Red horizontal bar represents the covariate being evaluated with values of the 10th and 90th percentiles of the covariate distribution displayed for continuous covariate in the square brackets. The length of each bar describes the impact of that particular covariate on tremelimumab exposure metric, with the percent change of exposure from the typical value being displayed (bold blue). Since no covariate reached the clinical significance threshold (30%), none were kept in the final PK model of tremelimumab; AUC_{ss}, area under the curve steady state (derived from analytical solution Dose/CL); CRP, C-reactive protein.